Parinox 80 Injection
Parinox 80 InjectionDescriptionEnoxaparin is a low molecular weight heparin with a high anti-Xa activity and with a low anti-lla or anti- thrombin activity. At doses required for the various indications, Enoxaparin does not increase bleeding time. At preventive doses, Enoxaparin causes no notable modification of activated Partial Thromboplastin Time (aPTT). It neither influences platelet aggregation nor binding of fibrinogen to platelets. Enoxaparin is primarily metabolized in the liver.IndicationsEnoxaparin is indicated for:Treatment of deep vein thrombosis, with or without pulmonary embolism.Treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently withaspirin.Prevention of thrombus formation in the extra-corporal circulation during haemodialysis.Prophylaxis of venous thromboembolic disease (prevention of blood clot formation in the veins), inparticular those which may be associated with orthopedic or general surgery.Prophylaxis of venous thromboembolic disease in medical patients bedridden due to acute illness,including cardiac insufficiency, respiratory failure, severe infections, rheumatic diseases.Dosage & AdministrationDosage adjustment in renal impairmentNo dosage adjustment is required in patients with moderate (creatinine clearance 30-50 ml/min) and mild (creatinine clearance 50-80 ml/min) renal impairment. But, all such patients should be observed carefully for signs and symptoms of bleeding.For patients with severe (creatinine clearance <30 ml/min) renal impairment the dosage adjustment for Prophylactic dose is: 2000 IU once daily and Therapeutic dose is: 100 IU/kg once daily.Elderly: No dosage adjustment is necessary, unless kidney function is impaired.Children: Safety and effectiveness of Enoxaparin in pediatric patients have not been established.Side EffectsHaemorrhage (bleeding), Thrombocytopenia, elevations of serum aminotransferase. Pain, bluish marks at injection sites to skin rash at injection sites. Cases of neuraxial hematomas with the concurrent use of Enoxaparin and spinal/epidural anesthesia or spinal puncture have resulted in varying degrees of neurologic injuries.PrecautionsEnoxaparin injection should not be administered by intramuscular route. Enoxaparin should be used with caution in conditions with increased potential for bleeding, such as impaired hemostasis, history of peptic ulcer, recent ischemic stroke, uncontrolled severe arterial hypertension, diabetic retinopathy, recent neuro or opthalmologic surgery and low weight patients. It is recommended that the platelet count be measured befored the initiation of the treatment and regularly thereafter during treatment.Use in Pregnancy & LactationPregnancyPregnancy category B. In humans, there is no evidence that Enoxaparin crosses the placental barrier Enoxaparin should be used during pregnancy only if the physician has established a clear need. Enoxaparin is not recommended for use in pregnant women with prosthetic heart valves.LactationIt is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Enoxaparin injection is administered to nursing women.Over DoseAccidental overdosage following administration of Enoxaparin may lead to hemorrhagic complications. Injected Enoxaparin may be largely neutralized by the slow i.v. injection of protamine sulfate (1% solution) The dose of protamine sulfate should be equal to the dose of Enoxaparin injected: 1 mg protamine sulfate should be administered to neutralize 1 mg Enoxaparin.StorageEnoxaparin should be stored below 25° C. Do not freeze...
Tk.650.00/=
Peg-Filastin Injection 0.6ml
Peg-Filastin Injection 0.6mlDescriptionPegfilgrastim is a covalent conjugate of recombinant methionyl human G-CSF (Filgrastim) and monomethoxypolyethylene glycol. Filgrastim is a water-soluble 175 amino acid protein with a molecular weight of approximately 19 kilodaltons (kD). Filgrastim is obtained from the bacterial fermentation of a strain of E. coli transformed with a genetically engineered plasmid containing the human G-CSF gene. To produce Pegfilgrastim, a 20 kD monomethoxypolyethylene glycol molecule is covalently bound to the N-terminal methionyl residue of Filgrastim. The average molecular weight of Pegfilgrastim is approximately 39 kD.IndicationsPegfilgrastim is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving Myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Pegfilgrastim is also indicated to increase survival in patients acutely exposed to Myelosuppressive doses of radiation.Dosage & AdministrationCancer patients receiving Myelosuppressive Chemotherapy: The recommended dosage of Pegfilgrastim is a single subcutaneous injection of 6 mg administered once per chemotherapy cycle in adults. For pediatric patients weight less than 10 kg is 0.1 mg (0.01ml)/kg, 10-20 kg is 0.15 ml, 21-30 kg is 0.25 ml & 31-44 kg is 0.4 ml. Do not administer Pegfilgrastim between 14 days before and 24 hours after administration of cytotoxic chemotherapy.Hematopoietic Subsyndrome of Acute Radiation Syndrome: The recommended dose of Pegfilgrastim is two doses of 6 mg each, administer the first dose as soon as possible after suspected or confirmed exposure to radiation levels greater than 2 gray (Gy) & the second dose one week after the first dose. For dosing in pediatric patients weighing less than 45 kg, refer to Myelosuppressive Chemotherapy dosing system.Side EffectsSplenic rupture, acute respiratory distress syndrome, serious allergic reactions, sickle cell crises, glomerulonephritis, leukocytosis, capillary leak syndrome and potential for tumor growth stimulatory effects of malignant cells may occur.PrecautionsMifepristone & Misoprostol combination should not give to anyone else. Administration must be under the supervision of a qualified physician. The combination of Mifepristone & Misoprostol has been prescribed for the patients specific condition, it may not be the correct treatment for another patients, and may be dangerous to the other women if she is or were to become pregnant. Any intrauterine device (IUD) should be removed before treatment with Mifepristone begins. Menstrual Regulation (MR) by surgery is recommended in cases when combination of Mifepristone & Misoprostol fails to cause Menstrual Regulation. Patients who have an ongoing pregnancy at last visit have a risk of fetal malformation resulting from the treatment. Surgical termination/MVA (Manual vaccum Aspiration) is recommended to manage Menstrual Regulation (MR)/termination of pregnancy failures.Use in Pregnancy & LactationPregnancy: Pregnancy category C. There are no adequate and well-controlled studies in pregnant women. Therefore, Pegfilgrastim should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.Lactation: It is not known whether Pegfilgrastim is secreted in human milk. Other recombinant G-CSF products are poorly secreted in breast milk and G-CSF is not orally absorbed by neonates. Caution should be exercised when administered to a nursing woman.Use in special populationPediatric use: The safety and effectiveness of Pegfilgrastim have not been established. Geriatric use: No overall differences in safety or effectiveness were observed in patients with age 65 and older.Drug InteractionNo formal drug interaction studies between Pegfilgrastim and other drugs have been performed.Over DoseThe maximum amount of Pegfilgrastim that can be safely administered has not been determined.StoragePegfilgrastim should be stored at 2-8ºC & avoid shaking before injection. Don’t store it at room temperature for more than 48 hours. Do not administer this product if discoloration or particulates are observed...
Tk.15,000.00/=
Pertuza 420 IV Infusion 14ml
Pertuza 420 IV Infusion 14mlDescriptionPertuzumab is a recombinant humanized monoclonal antibody that targets the extracellulardimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2).Pertuzumab targets the extracellular dimerization domain (Subdomain II) of the human epidermalgrowth factor receptor 2 protein (HER2) and, thereby, blocks ligand-dependent heterodimerization ofHER2 with other HER family members, including EGFR, HER3, and HER4. As a result, Pertuzumabinhibits ligand-initiated intracellular signaling through two major signal pathways, mitogen-activatedprotein (MAP) kinase, and phosphoinositide 3-kinase (PI3K). Inhibition of these signaling pathwayscan result in cell growth arrest and apoptosis, respectively. In addition, Pertuzumab mediatesantibody-dependent cell-mediated cytotoxicityIndicationsPertuzumab is a HER2/neu receptor antagonist indicated for:- Use in combination with Trastuzumab and docetaxel for treatment of patients with HER2-positivemetastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapyfor metastatic disease- Use in combination with Trastuzumab and docetaxel as neoadjuvant treatment of patients withHER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.This indication is based on demonstration of an improvement in pathological complete responserate. No data are available demonstrating improvement in event-free survival or overall survival.Limitations of Use:The safety of Pertuzumab as part of a doxorubicin-containing regimen has not been establishedThe safety of Pertuzumab administered for greater than 6 cycles for early breast cancer has not beenestablished.Dosage & AdministrationFor intravenous infusion only. It should not be administered as an intravenous push or bolusThe initial Pertuzumab dose is 840 mg administered as a 60-minute intravenous infusion, followedevery 3 weeks thereafter by 420 mg administered as a 30 to 60 minute intravenous infusionMBC: Pertuzumab should be administered with Trastuzumab and Docetaxel by intravenous infusionevery 3 weeksNeoadjuvant: Pertuzumab should be administered with Trastuzumab and Docetaxel by intravenousinfusion preoperatively every 3 weeks for 3 to 6 cyclesInstruction of UsesPertuzumab should be administered as an intravenous infusion only. It should not be administered asan intravenous push or bolus. Pertuzumab should not be used with other drugs.Side Effects- Left Ventricular Dysfunction: Pertuzumab can result in subclinical and clinical cardiac failuremanifesting as CHF, and decreased LVEF. Evaluate cardiac function prior to and during treatment.Discontinue Pertuzumab treatment for a confirmed clinically significant decrease in left ventricularfunction- Embryo-fetal Toxicity: Exposure to Pertuzumab can result in embryo-fetal death and birth defects.Studies in animals have resulted in oligohydramnios, delayed renal development, and death.Patients should be advised of these risks and the need for effective contraception.Metastatic Breast CancerThe most common adverse reactions (> 30%) with Pertuzumab in combination with Trastuzumaband Docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheralneuropathy.Neoadjuvant Treatment of Breast Cancer:The most common adverse reactions (> 30%) with Pertuzumab in combination with Trastuzumaband Docetaxel were alopecia, diarrhea, nausea, and neutropeniaThe most common adverse reactions (>30%) with Pertuzumab in combination with Trastuzumaband Docetaxel when given for 3 cycles following 3 cycles of fluorouracil, epirubicin, and cyclophosphamide(FEC) were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropeniaThe most common adverse reactions (>30%) with Pertuzumab in combination with Docetaxel,Carboplatin, and Trastuzumab (TCH) were fatigue, alopecia, diarrhea, nausea, vomiting,neutropenia, thrombocytopenia, and anemiaPrecautionsLeft Ventricular Dysfunction: LVEF should be monitored and dosing should be withheld as appropriateEmbryo-fetal toxicity: Fetal harm can occur when administered to a pregnant womanInfusion-Related Reactions: Should be monitored for signs and symptoms. If a significantinfusion-associated reaction occurs, the infusion should be slowed or interrupted and appropriatemedical therapies should be administeredHypersensitivity Reactions/Anaphylaxis: Should be monitored for signs and symptoms. If a severehypersensitivity reaction/anaphylaxis occurs, the infusion should be discontinued immediately andappropriate medical therapies should be administeredUse in Pregnancy & LactationPregnancy Category DThere are no adequate and well-controlled studies of Pertuzumab in pregnant women. If Pertuzumabis administered during pregnancy or if a patient becomes pregnant while receiving Pertuzumab orwithin 7 months following the la..
Tk.70,000.00/=
Rex 6/200/50 mg tablet 30's pack
Indication:Reduces risks of cardiovascular diseases in human, reduces risks of cataract, combats infection and chronic diseases, trend toward decreased age-related degenerative changes, defense against infection.Dosage & Administration:1 tablet daily.Preparation:Rex® tablets: Each bottle contains 30 tablets in bottle...
Tk.90.00/=
Ryzodeg Flextouch 5*3ml 5 x 3 ml
Insulin works by lowering levels of glucose (sugar) in the blood. Insulin aspart is a short-acting form of insulin. Insulin degludec is a long-acting insulin.Insulin aspart and insulin degludec is a combination medicine used to treat diabetes in adults. This medicine may be used for type 1 (insulin-dependent) or type 2 (noninsulin-dependent) diabetes.To make sure this medicine is safe for you, tell your doctor if you have:liver or kidney disease;low levels of potassium in your blood;if you take any oral (taken by mouth) diabetes medicine; orif you are in a state of diabetic ketoacidosis (call your doctor for treatment with insulin).It is not known whether this medicine passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby. Your dose needs may be different while you are nursing...
Tk.1,895.00/=
Servipep tab 20 mg
Famotidine is indicated for-Short term treatment of active duodenal ulcer and benign gastric ulcerMaintenance therapy for prevention of relapses of duodenal ulcerationGastro-oesophageal reflux diseaseZollinger Ellison Syndrome..
Tk.4.00/=
SIGLIMET 50/500 mg Tab.
Indication:Management of type 2 diabetes mellitus.Dosage & Administration:Dose of this combination should be individualized on the basis of the patient’s current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg Sitagliptin and 2000 mg Metformin.Administer once daily with meal preferably in the evening. Gradually escalate the dose to reduce the gastrointestinal side effects due to Metformin. May adjust the dosing based on effectiveness & tolerability while not exceeding the maximum daily dose of 100 mg Sitagliptin & and 2000 mg Metformin extended-release. Maintain the same total daily dose when changing between Siglimet™ & Siglimet™ XR without exceeding the maximum recommended daily dose of 2000 mg Metformin extended-release. Patients using two Siglimet™ XR tablets (such as two Siglimet XR 50/500 or two Siglimet™ XR 50/1000 tablets) should take the two tablets together once daily. 100 mg Sitagliptin/2000 mg Metformin HCl XR tablets should be taken as a single tablet once daily.Preparation:Siglimet™ 50/500 Tablet: Each box contains 30 tablets in blister pack.Siglimet™ 50/1000 Tablet: Each box contains 20 tablets in blister pack.Siglimet™ XR 50/500 Tablet: Each box contains 18 tablets in blister pack.Siglimet™ XR 50/1000 Tablet: Each box contains 18 tablets in blister pack.Siglimet™ XR 100/1000 Tablet: Each box contains 12 tablets in blister pack...
Tk.14.00/=
SULTOLIN 100 mcg Inhaler (MDI)
Salbutamol 100mcg/puff or actuation; metered dose inhalation (MDI). 200 dose unit: 250.00 MRPIndication:Salbutamol HFA Inhaler is indicated for the treatment or prevention of bronchospasm in adults and children 4 years of age and older with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm in patients 4 years of age and older.Dosage & Administration:For treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms, the usual dosage for adults and children 4 years of age and older is 2 inhalations repeated every 4 to 6 hours; in some patients , 1 inhalation every 4 hours may be sufficient. More frequent administration or a larger number of inhalations is not recommended. Exercise-Induced Bronchospasm Prevention: The usual dosage for adults and children 4 years and older is 2 inhalations 15 to 30 minutes before exercise.Preparation:Each Inhaler delivers 200 puffs..
Tk.250.00/=
Tab. Glycenor 10 mg
Empagliflozin is indicated in:As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease...
Tk.25.00/=
Telmacal 5/40 mg Tablet
1. What is Telmacal®?Telmacal® is the combination of Telmisartan and Amlodipine.2. How Telmacal® works in our body?Telmisartan is an angiotensin II receptor antagonist. Telmisartan keeps blood vessels from narrowing, which lowers blood pressure and improves blood flow.Amlodipine is a Dihydropyridine calcium channel blocker. Amlodipine relaxes (widens) blood vessels and improves blood flow.3. What is the indication of Telmacal®?This combination is used for the treatment of essential hypertension in adults.Replacement Therapy: Patients receiving Telmisartan and amlodipine from separate tablets may instead receive Telmisartan & Amlodipine containing the same component doses.Add-On Therapy: Telmisartan & Amlodipine is indicated in patients whose blood pressure is not adequately controlled on Telmisartan or amlodipine monotherapy.Initial Therapy: Telmisartan & Amlodipine may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Base the choice of Telmisartan & Amlodipine tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Telmisartan & Amlodipine tablets.Patients with moderate or severe hypertension are at relatively high-risk for cardiovascular events (eg, stroke, heart attacks and heart failure), kidney failure and vision problems, so prompt treatment is clinically relevant. Consider the patient’s baseline blood pressure, the target goals and the incremental likelihood of achieving goals with a combination compared to monotherapy when deciding whether to use Telmisartan & Amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk.4. What are the dosage & administration of Telmacal ®?Each tablet contains Telmisartan 40 mg & Amlodipine 5 mgAdults: One tablet should be taken once daily. Maximum Recommendation Dose: two tablets/day.Replacement Therapy: Patients receiving Telmisartan and amlodipine from separate tab can instead receive. Telmisartan & Amlodipine containing the same component doses in 1 tablet once daily eg, to enhance convenience or compliance.Add-On Therapy: Telmisartan & Amlodipine may be administered in patients whose blood pressure is not adequately controlled with amlodipine or Telmisartan alone. Patients treated with amlodipine 10 mg who experience any dose-limiting adverse reactions e.g., edema, may be switched to Telmisartan & Amlodipine 40/5 mg once daily, reducing the dose of amlodipine without reducing the overall etched antihypertensive response.Individual dose titration with the components (i.e., Amlodipine and Telmisartan) is recommended before changing to the fixed-dose combination. When clinically appropriate, direct change from monotherapy to the fixed-dose combination may be considered.Initial Therapy: A patient may be initiated on Telmisartan & Amlodipine if it is unlikely that control of blood pressure would be achieved with a single agent.Usual Starting Dose: 40/5 mg once daily. Initial therapy with Telmisartan & Amlodipine is not recommended in patients 75 years or with hepatic impairment. Correct imbalances on intravascular volume- or salt-depletion, before initiating therapy with Telmisartan & Amlodipine tablet.Telmisartan & Amlodipine may be taken with or without food.Children and Adolescents: Telmisartan & Amlodipine is not recommended for use in patients below 18 years due to a lack of data on safety and efficacy.Elderly: No dose adjustment is necessary for elderly patients. Limited information is available in the very elderly patients.5. What are the contraindications of Telmacal®?Hypersensitivity to Telmisartan, amlodipine, dihydropyridine derivatives or to any of the excipients of Telmisartan & Amlodipine. Biliary obstructive disorders, severe hepatic impairment & hypotension, cardiogenic shock, left ventricle outflow tract obstruction, hemodynamically unstable heart failure after acute MI.6. What are the adverse effects of Telmacal®?The most common adverse reactions include Dizziness, peripheral edema. Somnolence, migraine, headache, paresthesia, vertigo, bradycardia, palpitations, hypotension, orthostatic hypotension, flushing, cough, abdominal pain, diarrhea, nausea, pruritus, arthralgia, muscle spasms, myalgia, erectile dysfunction, asthenia, chest pain, fatigue, edema, increased hepatic enzyme.7. What would be the storage condition of Telmacal®?Keep in a dry place, below 30° C. Protect from light. Keep out of the reach of children.MoreoverTelma® 80 is available which is a preparation of TelmisartanTelma® Plus 40 is available which is a combination of Telmisartan and Hydrochlorothiazide. Telmacal Prescribing Information..
Tk.12.50/=
Ticamet 250 Inhaler (MDI)
Ticamet 250 Inhaler (MDI): Each actuation or dose contains salmeterol xinafoate BP 25mcg and fluticasone propionate BP 250mcg; metered dose inhalation.Ticamet 250 (120 doses unit) x l's pack: 752.83 MRPBIndication:Ticamet is indicated in the regular treatment of asthma, where use of a combination (LABA + Steroid) has been found to be appropriate. It is also effective for COPD patients.Dosage & Administration:Adults and adolescents 12 years and older: 2 puffs twice daily.Preparation:Ticamet 125 HFA: Salmeterol 25 mcg + Fluticasone 125 mcg/puffTicamet 250 HFA: Salmeterol 25 mcg + Fluticasone 250 mcg/puffTicamet 250 HFA Refill: Salmeterol 25 mcg + Fluticasone 250 mcg/puff..
Tk.797.00/=
Tofen 100 ml Syp
Tofen 100 ml SypTofen® is a preparation of Ketotifen which has antiallergic & anti-anaphylactic properties is used in the prophylactic treatment of bronchial asthma & symptomatic treatment of allergic conditions including rhinitis & conjunctivitis.The prophylactic activity of Tofen® may take several weeks to become fully established. Tofen® will not abort established attacks of asthma.Excellent option for respiratory problems in? preasthmatics’.Effective prophylaxis for asthmaEnsures allergy free life of the patientsEnsures better control of asthma & wheezingProtects against allergic respiratory and skin problemsIncreases appetite in children Tofen Prescribing Information..
Tk.65.00/=
Tory 120 mg Tablet
Tory 120 mg TabletIndication:Relief of pain and inflammation in - osteoarthritis, rheumatoid arthritis, other chronic musculoskeletal disorders, acute gout, dysmenorrhoea, & following dental surgery.Dosage & Administration:Adult and adolescent over 16 years: osteoarthritis, chronic musculoskeletal disorders & dysmenorrhoea: 60 mg, once daily, rheumatoid arthritis: 90 mg, once daily, pain following dental surgery & acute gout: 120 mg, once daily.Preparation:Tory ® 60 Tablet : Box containing 6 x 5 tablets in blister pack.Tory ® 90 Tablet : Box containing 6 x 5 tablets in blister pack.Tory ® 120 Tablet : Box containing 4 x 5 tablets in blister pack...
Tk.14.10/=
Tory 90 mg Tablet
Tory 90 mg TabletIndication:Relief of pain and inflammation in - osteoarthritis, rheumatoid arthritis, other chronic musculoskeletal disorders, acute gout, dysmenorrhoea, & following dental surgery.Dosage & Administration:Adult and adolescent over 16 years: osteoarthritis, chronic musculoskeletal disorders & dysmenorrhoea: 60 mg, once daily, rheumatoid arthritis: 90 mg, once daily, pain following dental surgery & acute gout: 120 mg, once daily.Preparation:Tory ® 60 Tablet : Box containing 6 x 5 tablets in blister pack.Tory ® 90 Tablet : Box containing 6 x 5 tablets in blister pack.Tory ® 120 Tablet : Box containing 4 x 5 tablets in blister pack...
Tk.12.00/=
Tresiba Flex Touch ( 1 Pre Filled Syringe)
How to useTresiba® can be injected under the skin (subcutaneously) of your upper legs (thighs), upper arms, or stomach area (abdomen)It’s important to change the injection site within your injection area each time you inject and not inject into the exact same spot each timeRotating where you inject allows your body to absorb the insulin and can help to prevent skin changes such as thickening or pitting, known as lipodystrophyIngredient Prescription Tresiba® is a long-acting insulin used to control high blood sugar in adults with diabetesTresiba® is not for people with diabetic ketoacidosisTresiba® is available in 2 concentrations: 200 units/mL and 100 units/mLIt is not known if Tresiba® is safe and effective in children under 18 years of age..
Tk.2,490.00/=
Tresiba FlexTouch 100 IU/ml
insulin Degludec is indicated for once-daily treatment of adults with diabetes mellitus to improve glycemic control. Insulin Degludec is not recommended for the treatment of diabetic ketoacidosis...
Tk.2,490.00/=
Vibrenta 3ml (100 iu vial)
কোম্পানির নাম: Incepta Pharmaceuticals Ltd.জেনেরিক নাম : Insulin Glargin rDNAQuick Overview:Vibrenta (Insulin glargine [rDNA] injection) is a sterile solution of insulin glargine for use as a subcutaneous injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenteral blood-glucose-lowering agent. Vibrenta is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism.Primary function of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, primarily by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain.DescriptionVibrenta (Insulin glargine [rDNA] injection) is a sterile solution of insulin glargine for use as a subcutaneous injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenteral blood-glucose-lowering agent. Vibrenta is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism.Primary function of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, primarily by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain.IndicationsVibrenta is indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.Dosage & AdministrationVibrenta exhibits a relatively constant glucose-lowering profile over 24 hours that permits once-daily dosing. Potency of insulin glargine is approximately the same as human insulin.Vibrenta is recommended for once daily subcutaneous administration & may be administered at any time during the day. However, once started should be administered at the same time every day. The dose of Vibrenta must be individualized based on clinical response. Blood glucose monitoring is essential in all patients with diabetes. In patients with type 1 diabetes, Vibrenta must be used in regimens with short-acting insulin. Vibrenta is not recommended for intravenous administration. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycemia.Injection sites should be rotated within the same region (abdomen, thigh, or deltoid) from one injection to the next.Initiation of Vibrenta therapyThe recommended starting dose of Vibrenta in patients with type 1 diabetes should be approximately one-third of the total daily insulin requirements. Short-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements.The recommended starting dose of Vibrenta in patients with type 2 diabetes who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted to the patient\'s needs.Converting to Vibrenta from other insulin therapiesIf changing from a treatment regimen with an intermediate- or long-acting insulin to a regimen with Vibrenta, the amount and timing of shorter-acting insulins and doses of any oral anti-diabetic drugs may need to be adjusted.If transferring patients from once-daily NPH insulin to once-daily Vibrenta, the recommended initial Vibrenta dose is the same as the dose of NPH that is being discontinuedIf transferring patients from twice-daily NPH insulin to once-daily Vibrenta, the recommended initial Vibrenta dose is 80% of the total NPH dose that is being discontinuedInstructions to be given to the patientVialBefore injecting this Insulin:1. Disinfect the rubber stopper.2. Draw into the syringe the same amount of air as the dose of insulin to be injected.3. Inject the air into the vial.4. Turn the vial and syringe upside down and draw the correct insulin dose into the syringe. Withdraw the needle from vial and expel the air from the syringe and check that the dose is correct.5. Inject immediately.CartridgeBefore injecting this Insulin:1. According to the instruction given with ConviPen, insert the Vibrenta cartridge into the pen correctly & equip the needle2. Remove the needle cap, discharge air bubbles in the catridge3. Adjust the dosage button to get correct dose & inject to the specific site4. In order to avoid cross contamination, do not let the ..
Tk.600.00/=
Victoza 6mg 1x3ml
Victoza is indicated for treatment of adults with type 2 diabetes mellitus to achieve glycaemic control as Monotherapy.When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance or contraindications.Effects on ability to drive and use machinesVictoza has no or negligible influence on the ability to drive and use machines.Patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines, in particular when Victoza is used in combination with a sulfonylurea or a basal insulin...
Tk.4,960.00/=
Voligel Cream 50 gm
Voligel Cream 50 gmWhat is Voligel®?Voligel® gel is a combination of three different components namely Diclofenac, Methyl salicylate, and Menthol.Diclofenac Diethylamine is systemically absorbed through the skin; it inhibits the enzyme cyclo-oxygenase, thus reducing the formation of PGE2. Moreover, it also increases the uptake of arachidonic acid into the cellular pool. Menthol is a vasodilator. It dilates the blood vessels, produces a feeling of coolness and produces analgesia. Methyl salicylate is a known anti-inflammatory agent.Adding diclofenac with these components helps not only the sensation of pain but also treats any underlying inflammation at the affected area. Diclofenac also exerts synergistic effect on pain relief.When to take Voligel®?Indicated for the quick relief from pain, swelling and inflalmmation due to musculo-skeletal disorders such as sprains, Strains, tendinitis, bursitis, hands, neck & shoulder pain, sciatica, muscle stiffness, joint pain, back ache and lumbago.How to take Voligel®?Voligel® cream should be applied to the affected site three to four times daily with rubbing till the film disappears.Who should not take Voligel®?Those who have known hypersensitivity to any part of the preparation.How Voligel® works?Diclofenac inhibits the enzyme cyclo-oxygenase, thus reducing the inflammation and painMenthol produces a feeling of coolness and produces comfort and analgesiaMethyl salicylate is a also a mild anti-inflammatory agent.How supplied?Voligel® gel: Box containing 50 gm tube. Each 100 gm Gel contains Diclofenac Diethylamine BP 1.16 gm (eq. to Diclofenac Sodium 1 gm). Voligel Prescribing information..
Tk.97.00/=
Glyset Mix inj
Glyset Mix injDescriptionGlyset Mix (insulin aspart protamine and insulin aspart) is a sterile suspension of human insulin analog containing30% soluble insulin aspart and 70% protamine-crystallised insulin aspart. Glyset Mix is a blood glucose loweringagent with an earlier onset and an intermediate duration of action. Insulin Aspart is homologous with regular humaninsulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28, and isproduced by recombinant DNA technology.IndicationsGlyset Mix is an insulin analog indicated to improve glycemic control in patients with diabetes mellitus.Dosage & AdministrationDosage of Glyset Mix is individual and determined by the physician in accordance with the needs of the patient.In patients with type 2 diabetes, Glyset Mix can be given in mono therapy or in combination with oral antidiabeticdrugs when the blood glucose is inadequately controlled with those oral antidiabetic drugs alone. For patients withtype 2 diabetes, the recommended starting dose of Glyset Mix is 6 IU at breakfast and 6 IU at dinner (evening meal).Glyset Mix can also be initiated once daily with 12 IU at dinner (evening meal). When using Glyset Mix once daily, itis generally recommended to move to twice-daily when reaching 30 units by splitting the dose into equal breakfastand dinner doses. If twice daily dosing with Glyset Mix results in recurrent daytime hypoglycaemic episodes, themorning dose can be split into morning and lunchtime doses (thrice daily dosing).The dose should not be increased if hypoglycemia occurred within three days. Dose adjustments can be made oncea week until target HbA1c is reached.In patients with type 1 diabetes the individual insulin requirement is usually between 0.5 and 1.0 IU/kg/day. GlysetMix may fully or partially meet this requirement. When transferring a patient from biphasic human insulin to GlysetMix, start with the same dose and regimen. Then titrate according to individual needs (according to the titrationguidelines in table above). Glyset Mix can be used in elderly patients; however there is limited experience with theuse of Glyset Mix in combination with OADs in patients older than 75 years.For details,please see enclosed leafletSide EffectsSide effects of Insulin Aspart are hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus andrash.PrecautionsDose adjustment and monitoring: Blood glucose should be monitored in all patients treated with insulin. Insulinregimens should be modified cautiously and only under medical supervision.Use in Pregnancy & LactationPregnancy: Pregnancy category B.Lactation: There are no restrictions on treatment with Glyset Mix during lactation. Insulin treatment of the nursingmother should not affect the baby. However, dosage may need to be adjusted.Drug InteractionA number of drugs affect glucose metabolism and may require dose adjustment.The following substances may reduce the Insulin as well as Insulin Aspart requirements:Oral anti-diabetic products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine,monoamine oxidase inhibitors, propoxyphene, pentoxifylline, salicylates and sulfonamide antibiotics.The following substances may increase the Insulin as well as Insulin Aspart requirements:Thiazides, glucocorticoids, thyroid hormones, beta-sympathomimetics, growth hormone and danazol.Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood glucose lowering effectof insulin.Over DoseA specific overdose for insulin cannot be defined, however, hypoglycaemia may develop over sequential stages if toohigh doses relative to the patient’s requirement are administered.Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products.Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1mg) given intramuscularly or subcutaneously. Glucose must also be given intravenously if the patient does notrespond to glucagon within 10 to 15 minutes.Upon regaining consciousness administration of oral carbohydrate is recommended for the patient in order toprevent relapse...
Tk.450.00/=
Glyset Mix Penset Inj
Glyset Mix Penset InjDescriptionGlyset Mix (insulin aspart protamine and insulin aspart) is a sterile suspension of human insulin analog containing30% soluble insulin aspart and 70% protamine-crystallised insulin aspart. Glyset Mix is a blood glucose loweringagent with an earlier onset and an intermediate duration of action. Insulin Aspart is homologous with regular humaninsulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28, and isproduced by recombinant DNA technology.IndicationsGlyset Mix is an insulin analog indicated to improve glycemic control in patients with diabetes mellitus.Dosage & AdministrationDosage of Glyset Mix is individual and determined by the physician in accordance with the needs of the patient.In patients with type 2 diabetes, Glyset Mix can be given in mono therapy or in combination with oral antidiabeticdrugs when the blood glucose is inadequately controlled with those oral antidiabetic drugs alone. For patients withtype 2 diabetes, the recommended starting dose of Glyset Mix is 6 IU at breakfast and 6 IU at dinner (evening meal).Glyset Mix can also be initiated once daily with 12 IU at dinner (evening meal). When using Glyset Mix once daily, itis generally recommended to move to twice-daily when reaching 30 units by splitting the dose into equal breakfastand dinner doses. If twice daily dosing with Glyset Mix results in recurrent daytime hypoglycaemic episodes, themorning dose can be split into morning and lunchtime doses (thrice daily dosing).The dose should not be increased if hypoglycemia occurred within three days. Dose adjustments can be made oncea week until target HbA1c is reached.In patients with type 1 diabetes the individual insulin requirement is usually between 0.5 and 1.0 IU/kg/day. GlysetMix may fully or partially meet this requirement. When transferring a patient from biphasic human insulin to GlysetMix, start with the same dose and regimen. Then titrate according to individual needs (according to the titrationguidelines in table above). Glyset Mix can be used in elderly patients; however there is limited experience with theuse of Glyset Mix in combination with OADs in patients older than 75 years.For details,please see enclosed leafletSide EffectsSide effects of Insulin Aspart are hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus andrash.PrecautionsDose adjustment and monitoring: Blood glucose should be monitored in all patients treated with insulin. Insulinregimens should be modified cautiously and only under medical supervision.Use in Pregnancy & LactationPregnancy: Pregnancy category B.Lactation: There are no restrictions on treatment with Glyset Mix during lactation. Insulin treatment of the nursingmother should not affect the baby. However, dosage may need to be adjusted.Drug InteractionA number of drugs affect glucose metabolism and may require dose adjustment.The following substances may reduce the Insulin as well as Insulin Aspart requirements:Oral anti-diabetic products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine,monoamine oxidase inhibitors, propoxyphene, pentoxifylline, salicylates and sulfonamide antibiotics.The following substances may increase the Insulin as well as Insulin Aspart requirements:Thiazides, glucocorticoids, thyroid hormones, beta-sympathomimetics, growth hormone and danazol.Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood glucose lowering effectof insulin.Over DoseA specific overdose for insulin cannot be defined, however, hypoglycaemia may develop over sequential stages if toohigh doses relative to the patient’s requirement are administered.Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products.Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1mg) given intramuscularly or subcutaneously. Glucose must also be given intravenously if the patient does notrespond to glucagon within 10 to 15 minutes.Upon regaining consciousness administration of oral carbohydrate is recommended for the patient in order toprevent relapse...
Tk.550.00/=
Glyset R Penset
Glyset R PensetDescriptionGlyset R (Insulin Aspart rDNA) is a sterile, clear solution of Insulin Aspart human insulin analogue forsubcutaneous injection/infusion or intravenous injection. Glyset R is a blood glucose lowering agentwith an earlier onset of action. Glyset R produces a more rapid onset of action compared to solublehuman insulin. Insulin Aspart is homologous with regular human insulin with the exception of a singlesubstitution of the amino acid Proline by aspartic acid in position B28, and is produced by recombinantDNA technology.IndicationsGlyset R is an insulin analog indicated to improve glycemic control in patients with diabetes mellitus.Instructions to be given to the patientBefore injecting this Insulin:1. According to the instruction given with ConviPen, insert the Glyset cartridge into the pen correctly &equip the needle2. In case of Glyset Mix, gently turn the pen upside down for 8-10 times until the insulin in the cartridgebecomes uniformly mixed suspension3. Remove the needle cap, discharge air bubbles in the catridge4. Adjust the dosage button to get correct dose & inject to the specific site5. In order to avoid cross contamination, do not let the needle touch anything during the process ofpreparation.For detail description, please see the Patient Instruction Leaflet provided with ConviPen.Dosage & AdministrationGlyset R has a faster onset and a shorter duration of action than soluble human insulin. Due to thefaster onset of action, Glyset R should generally be given immediately before a meal. When necessaryGlyset R may be given soon after a meal.Dosage of Glyset R is individual and determined on the basis of the physician's advice in accordancewith the needs of the patient. It should normally be used in combination with long-acting insulin givenat least once a day.The individual insulin requirement is usually between 0.5 and 1.0 IU/kg/day in adults and children over2 years of age. In a meal-related treatment 50-70% of this requirement may be provided by Glyset Rand the remainder by long-acting insulin. Adjustment of dosage may also be necessary if patientsundertake increased physical activity or change their usual diet. Exercise taken immediately after ameal may increase the risk of hypoglycaemia.Subcutaneous InjectionGlyset R should be administered by subcutaneous injection in the abdominal region, buttocks, thigh,or upper arm. Because Glyset R has a more rapid onset and a shorter duration of activity than humanregular insulin, it should be injected immediately (within 5-10 minutes) before a mealContinuous Subcutaneous Insulin Infusion (CSII) by External PumpGlyset R can also be infused subcutaneously by an external insulin pump. The initial programming ofthe external insulin infusion pump should be based on the total daily insulin dose of the previousregimen. Approximately 50% of the total dose is usually given as meal-related boluses of Glyset R andthe remainder is given as a basal infusion. When used with an infusion pump Glyset R should not bemixed with any other insulin.Intravenous UseGlyset R can be administered intravenously under medical supervision for glycemic control with closemonitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia. Forintravenous use, Glyset R should be used at concentrations from 0.05 IU/mL to 1.0 IU/mL insulinaspart in infusion systems using polypropylene infusion bags. Glyset R has been shown to be stable ininfusion fluids such as 0.9% sodium chloride.Side EffectsSide effects of Insulin Aspart are hypoglycemia, allergic reactions, injection site reaction,lipodystrophy, pruritus and rash.PrecautionsDose adjustment and monitoring: Blood glucose should be monitored in all patients treated withinsulin. Insulin regimens should be modified cautiously and only under medical supervisionUse in Pregnancy & LactationPregnancy: Pregnancy category B.Lactation: There are no restrictions on treatment with Glyset R during lactation. Insulin treatment of thenursing mother should not affect the baby. However, dosage may need to be adjusted.Drug InteractionA number of drugs affect glucose metabolism and may require dose adjustment.The following substances may reduce the Insulin as well as Insulin Aspart requirements:Oral anti-diabetic products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates,fluoxetine, monoamine oxidase inhibitors, propoxyphene, pentoxifylline, salicylates and sulfonamideantibiotics.The following substances may increase the Insulin as well as Insulin Aspart requirements:Thiazides, glucocorticoids, thyroid hormones, beta-sympathomimetics, growth hormone and danazol.Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood glucoselowering effect of insulin.Over DoseA specific overdose for insulin cannot be defined, however, hypoglycaemia may develop oversequential stages if too high doses relative to the patient’s requirement are administered.Mild ..
Tk.550.00/=
Glyset R Penset
Glyset R PensetDescriptionGlyset R (Insulin Aspart rDNA) is a sterile, clear solution of Insulin Aspart human insulin analogue forsubcutaneous injection/infusion or intravenous injection. Glyset R is a blood glucose lowering agentwith an earlier onset of action. Glyset R produces a more rapid onset of action compared to solublehuman insulin. Insulin Aspart is homologous with regular human insulin with the exception of a singlesubstitution of the amino acid Proline by aspartic acid in position B28, and is produced by recombinantDNA technology.IndicationsGlyset R is an insulin analog indicated to improve glycemic control in patients with diabetes mellitus.Instructions to be given to the patientBefore injecting this Insulin:1. According to the instruction given with ConviPen, insert the Glyset cartridge into the pen correctly &equip the needle2. In case of Glyset Mix, gently turn the pen upside down for 8-10 times until the insulin in the cartridgebecomes uniformly mixed suspension3. Remove the needle cap, discharge air bubbles in the catridge4. Adjust the dosage button to get correct dose & inject to the specific site5. In order to avoid cross contamination, do not let the needle touch anything during the process ofpreparation.For detail description, please see the Patient Instruction Leaflet provided with ConviPen.Dosage & AdministrationGlyset R has a faster onset and a shorter duration of action than soluble human insulin. Due to thefaster onset of action, Glyset R should generally be given immediately before a meal. When necessaryGlyset R may be given soon after a meal.Dosage of Glyset R is individual and determined on the basis of the physician's advice in accordancewith the needs of the patient. It should normally be used in combination with long-acting insulin givenat least once a day.The individual insulin requirement is usually between 0.5 and 1.0 IU/kg/day in adults and children over2 years of age. In a meal-related treatment 50-70% of this requirement may be provided by Glyset Rand the remainder by long-acting insulin. Adjustment of dosage may also be necessary if patientsundertake increased physical activity or change their usual diet. Exercise taken immediately after ameal may increase the risk of hypoglycaemia.Subcutaneous InjectionGlyset R should be administered by subcutaneous injection in the abdominal region, buttocks, thigh,or upper arm. Because Glyset R has a more rapid onset and a shorter duration of activity than humanregular insulin, it should be injected immediately (within 5-10 minutes) before a mealContinuous Subcutaneous Insulin Infusion (CSII) by External PumpGlyset R can also be infused subcutaneously by an external insulin pump. The initial programming ofthe external insulin infusion pump should be based on the total daily insulin dose of the previousregimen. Approximately 50% of the total dose is usually given as meal-related boluses of Glyset R andthe remainder is given as a basal infusion. When used with an infusion pump Glyset R should not bemixed with any other insulin.Intravenous UseGlyset R can be administered intravenously under medical supervision for glycemic control with closemonitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia. Forintravenous use, Glyset R should be used at concentrations from 0.05 IU/mL to 1.0 IU/mL insulinaspart in infusion systems using polypropylene infusion bags. Glyset R has been shown to be stable ininfusion fluids such as 0.9% sodium chloride.Side EffectsSide effects of Insulin Aspart are hypoglycemia, allergic reactions, injection site reaction,lipodystrophy, pruritus and rash.PrecautionsDose adjustment and monitoring: Blood glucose should be monitored in all patients treated withinsulin. Insulin regimens should be modified cautiously and only under medical supervisionUse in Pregnancy & LactationPregnancy: Pregnancy category B.Lactation: There are no restrictions on treatment with Glyset R during lactation. Insulin treatment of thenursing mother should not affect the baby. However, dosage may need to be adjusted.Drug InteractionA number of drugs affect glucose metabolism and may require dose adjustment.The following substances may reduce the Insulin as well as Insulin Aspart requirements:Oral anti-diabetic products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates,fluoxetine, monoamine oxidase inhibitors, propoxyphene, pentoxifylline, salicylates and sulfonamideantibiotics.The following substances may increase the Insulin as well as Insulin Aspart requirements:Thiazides, glucocorticoids, thyroid hormones, beta-sympathomimetics, growth hormone and danazol.Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood glucoselowering effect of insulin.Over DoseA specific overdose for insulin cannot be defined, however, hypoglycaemia may develop oversequential stages if too high doses relative to the patient’s requirement are administered.Mild ..
Tk.550.00/=
-170x150.jpg "Medicines")